GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease (NAFLD) in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).
Details for the oral presentation are as follows:
| Title: | Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibro-inflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial (Presentation ID OS-063) |
| Presenter: | Stephen A. Harrison, M.D., Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University |
| Date/Time: | Friday, June 23, 2023, at 8:30 am CEST |
Best of EASL Summary Slide Deck
Dr. Harrison’s presentation was selected for the Best of EASL Summary Slides, a compendium highlighting the most noteworthy contributions to the 2023 EASL program. A copy of the presentation will be accessible on the Events section of the Altimmune website.
NASH KOL and Investor Reception
Altimmune will host a reception in Vienna for NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST. Please click here if you are interested in attending the reception and to receive additional details.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.66 |
| Daily Change: | 0.35 4.79 |
| Daily Volume: | 6,572,773 |
| Market Cap: | US$544.780M |
November 12, 2024 November 07, 2024 October 15, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
